Previous close | 314.54 |
Open | 314.82 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 304.69 - 314.82 |
52-week range | 304.69 - 314.82 |
Volume | |
Avg. volume | N/A |
Market cap | 784.136M |
Beta (5Y monthly) | 0.44 |
PE ratio (TTM) | 0.32 |
EPS (TTM) | 9.48 |
Earnings date | 07 Feb 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The healthcare industry has proven to be a remarkably resilient place to put capital to work in a wide range of environments. From life-saving medicines and therapies to vaccines, these are just a few examples of the essential products that healthcare companies make that render them particularly defensive investments in a bearish environment. AbbVie (NYSE: ABBV) is a pharmaceutical giant.
Wouldn't it be nice if investors had an "easy button" like the one that was featured in Staples commercials years ago? Unfortunately, the "easy button" doesn't exist. Actually, Amazon's stock has already begun a rebound, up more than 20% year to date after plunging nearly 50% in 2022.